"Product Profiles: Insulin Antidiabetics - Key developers compete for basal insulins market" - New Market Report
The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012-13 will alter market dynamics.
View full press release